Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PF-05280014 plus paclitaxel versus trastuzumab plus paclitaxel in first-line HER2-positive metastatic breast cancer
2013-001352-34Phase 3Completed
- Sponsor
- Pfizer
- Start
- Sep 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in HER2-positive breast cancer comparing PF-05280014 plus paclitaxel with Trastuzumab plus paclitaxel (2 arms). Primary endpoint: Objective response rate. Started Sep 2013; status: completed.
02
Drugs
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on 2013-001352-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-001352-34.